AbCheck offers a variety of services and technologies to meet the increased demand for high-quality antibody development candidates in today’s antibody discovery world, where drug developers’ needs have grown beyond the classical set of lead and backup candidate with ADCC activity in IgG format, with projects now comprising discovery of multiple candidates, including antibodies that trigger changes on the cellular level as well as rare antibodies with narrow specificities.
Flexibly adapting to our partners’ needs, we offer customized solutions to discover and develop antibodies against challenging targets and antibodies with therapeutically relevant biological functions by selecting a technology set designed for your project’s specific needs from our unique suite of in vitro and in vivo approaches. We offer tailored discovery and optimization of human antibodies leveraging both cutting edge (e.g., microfluidics, rabbit mass humanization, single copy integration site technology) and classical (e.g. phage/yeast display libraries,) technologies to provide high-quality leads. Our cutting edge and classical technologies can be flexibly combined to meet specific customer needs.
Our unique microfluidics platform and screening process enables functional screening of millions of single cells/day to determine functional leads within ~3-4 months.
Microfluidics and library-based approaches can be bridged with the most recent addition to our technology suite, our single copy integration site technology.